Roche, Pfiz­er top list of ESG lead­ers in pa­tient group­s' view, but many still think phar­mas can do bet­ter

The rise of phar­ma en­vi­ron­men­tal, so­cial and gov­er­nance (ESG) ef­forts in the past two years has been me­te­oric as in­vestors turn their at­ten­tion to sus­tain­able fund­ing. How­ev­er, in­vestors aren’t the on­ly ones watch­ing. Pa­tients are be­gin­ning to tune in­to phar­mas’ ESG promis­es too.

Pa­tient ad­vo­ca­cy groups fa­mil­iar with ESG re­gard it as an im­por­tant is­sue and want to be in­clud­ed in help­ing phar­ma com­pa­nies set ESG poli­cies and tar­gets, ac­cord­ing to a new re­port from Pa­tientView. That’s quite dif­fer­ent from what the in­vest­ment com­mu­ni­ty wants across a va­ri­ety of Gart­ner’s de­fined fi­nan­cial, com­pet­i­tive, strate­gic and per­cep­tion goals.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.